Related Experiment Video
Updated: Oct 18, 2025
10:51
3D Cell-Printed Hypoxic Cancer-on-a-Chip for Recapitulating Pathologic Progression of Solid Cancer
Published on: January 5, 2021
4.9K
Recapitulating the Cancer Microenvironment Using Bioprinting Technology for Precision Medicine
Jisoo Kim1, Jinah Jang1,2,3,4, Dong-Woo Cho1,2,4
1School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea.
Micromachines
|September 28, 2021
Summary
Bioprinting advances create sophisticated in vitro cancer models that better mimic the tumor microenvironment, overcoming limitations of traditional methods for drug resistance studies and precision medicine applications.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Drug Discovery
Background:
- Cancer's complexity and heterogeneity drive drug resistance.
- The tumor microenvironment, including cell interactions and extracellular matrix (ECM), is crucial for drug resistance.
- Traditional animal models have limitations in replicating human cancer biology.
Purpose of the Study:
- To review bioprinted in vitro models for cancer research.
- To discuss fabrication strategies and essential factors for reconstructing the cancer microenvironment.
- To highlight applications in precision medicine and address challenges in 3D bioprinting.
Main Methods:
- Review of representative bioprinted in vitro cancer models.
- Analysis of fabrication strategies for microenvironment reconstruction.
- Examination of recent studies applying bioprinted models in cancer research and precision medicine.
Main Results:
- Bioprinting technologies offer potential to overcome limitations of conventional 2D and 3D in vitro models.
- Bioprinted models can better emulate complex cancer microenvironments.
- Advanced bioprinting enables fabrication of biomimetic cancer models for precision medicine.
Conclusions:
- Bioprinted in vitro models show promise for advancing cancer research and drug development.
- Further development is needed to address challenges in 3D bioprinting for clinical applications.
- Improved biomimetic models can enhance understanding of cancer pathophysiology and drug resistance.
